GBP104.92
0.71% yesterday
London, May 21, 05:38 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP104.92
+3.68 3.63% 1M
+5.74 5.79% 6M
+1.74 1.69% YTD
-16.20 13.38% 1Y
+5.49 5.52% 3Y
+25.10 31.44% 5Y
+72.63 224.88% 10Y
London, Closing price Wed, May 21 2025
+0.74 0.71%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP161.55b
Enterprise Value GBP181.11b
P/E (TTM) P/E ratio 28.28
EV/FCF (TTM) EV/FCF 26.59
EV/Sales (TTM) EV/Sales 4.42
P/S ratio (TTM) P/S ratio 3.94
P/B ratio (TTM) P/B ratio 5.32
Dividend yield 2.34%
Last dividend (FY24) GBP2.46
Revenue growth (TTM) Revenue growth 15.48%
Revenue (TTM) Revenue GBP40.99b
EBIT (operating result TTM) EBIT GBP9.86b
Free Cash Flow (TTM) Free Cash Flow GBP6.81b
Cash position GBP4.02b
EPS (TTM) EPS GBP3.71
P/E forward 21.09
P/S forward 3.75
EV/Sales forward 4.20
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

29x Buy
91%
3x Hold
9%

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

Buy
91%
Hold
9%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
40,986 40,986
15% 15%
100%
- Direct Costs 7,231 7,231
14% 14%
18%
33,755 33,755
16% 16%
82%
- Selling and Administrative Expenses 11,581 11,581
4% 4%
28%
- Research and Development Expense 9,395 9,395
18% 18%
23%
12,752 12,752
30% 30%
31%
- Depreciation and Amortization 2,894 2,894
1% 1%
7%
EBIT (Operating Income) EBIT 9,858 9,858
42% 42%
24%
Net Profit 5,794 5,794
23% 23%
14%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
Business Wire
about 20 hours ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2025. More than 80 abstracts will feature 20 approved and potential new medicines from the Company including two plenary present...
Positive
The Motley Fool
one day ago
Investing in growth stocks is a great way to grow your portfolio in the long run. But it can be difficult to predict which ones will take off in value and which one's won't.
Neutral
Business Wire
3 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published in the New E...
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today